Clinical trial NCT02306798: TP0502-B-Pharmaco-Scintigraphic-Study
Official title: An Open Label, Single-site Pharmaco-Scintigraphic Study in Healthy Subjects With Radio-labelled TP05-tablets (Mesalazine) to Evaluate the Gastrointestinal Transit and Release Profile
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Ulcerative Colitis
Lead sponsor: Tillotts Pharma AG
Sponsor class: INDUSTRY
First posted: 2014-12-03
Enrollment: 9
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: This is a Phase I, open-label, single-site trial to evaluate the drug release, using scintigraphic images and mesalazine plasma levels (PK) in healthy subjects. Overall, nine \[9\] subjects will be evaluated. The subjects will receive one \[1\] radio-labelled tablet after a high fat and a rich in calories breakfast.


Eligibility criteria: Inclusion Criteria:

1. Healthy subjects, male or non-pregnant, non-lactating females, between 18 and 55 years old. Females of child bearing potential must have a negative serum pregnancy test prior to the intake of study drug, and must use a hormonal (oral, implantable or injectable) or a double barrier method of birth control throughout the study. Females unable to bear children must have documentation of such in the source records (i.e., tubal ligation, hysterectomy, or post-menopausal \[defined as a minimum of one year since the last menstrual period\]).
2. Ability of subject to participate fully in all aspects of this clinical trial.
3. Written informed consent must be obtained and documented.

Exclusion Criteria:

1. Participating in a clinical study involving investigational drugs or dosage forms within the previous 30 days.
2. History of alcohol or drug abuse.
3. Radiation exposure from clinical trials, including that from the present study and from diagnostic X-ray but excluding background radiation, exceeds 5 mSv (milli-Sievert) in the last five years. No subject whose occupational exposure is monitored will participate in the study.
4. Any nuclear medicine procedure prior to study day 1 that might interfere with the scintigraphic images that are acquired.
5. Clinically significant abnormal biochemistry, haematology or urinalysis:

   * White blood count \<3 x 109/L and \>8 x 109/L
   * Lymphocyte count \< 0.85 x 109/L
   * Haemoglobin \< 110g/L
   * Platelet count \< 125 x 109/L or \> 600 x 109/L
   * Alanine-Aminotransferase (ALT) or Aspartate-Aminotransferase (AST) \> 2x upper limit of normal
   * Alkaline Phosphatase \> 2x upper limit of normal
   * Serum Creatinine \> upper limit of normal
6. History of gastrointestinal surgery, with the exception of appendectomy unless it was performed within the previous 12 months.
7. History of cardiovascular, renal, hepatic, respiratory and particularly gastrointestinal disease, especially peptic ulceration, gastrointestinal bleeding, ulcerative colitis, Crohn's disease or Irritable Bowel Syndrome (within the previous 12 months).
8. Acute diarrhoea or constipation in the 14 days before the predicted first study day. If screening occurs \>14 days before first study day, this criterion is to be determined on the first study day. Diarrhoea will be defined as the passage of liquid faeces and/or a stool frequency of greater than three times per day. Constipation will be defined as a failure to open the bowels more frequently than every other day.
9. History of adverse reaction or allergy to aspirin, mesalazine or other salicylates.
10. Donation of blood within the previous three months.
11. Positive HBV-Antigen (Hepatitis-B), HCV-Antibody (Hepatitis-C) or HIV-antibody (Human Immunodeficiency Virus) result.
12. Over-the-counter (OTC) and prescription medication (including laxatives, vitamins and natural herbal remedies) between screening visit (visit 1) and completion of the study. Occasional paracetamol or acetyl-salicylic acid is permitted.
13. Failure to satisfy the Principal Investigator to participate for any other reason.

Primary outcomes:
measure: Tablet release
timeFrame: 3 days
Secondary outcomes:
measure: Maximal Plasma Concentration (Cmax)
timeFrame: 3 days
measure: Time to reach Cmax (Tmax)
timeFrame: 3 days
measure: Area under the concentration time-curve
timeFrame: 3 days
measure: Elimination rate konstant (k)
timeFrame: 3 days
measure: Lag-time (t-lag)
timeFrame: 3 days
Other outcomes:
Locations:
Study officials:
References: